Tegoprubart preserves kidney function better than tacrolimus in first-time transplant patients, trial suggests
The phase 2 BESTOW clinical trial showed that tegoprubart (a novel anti-CD40L antibody therapy) was better at preserving kidney function than tacrolimus (the current standard of care) in immunosuppressive regimens in adults receiving their first kidney transplant. Kidney graft function stabilized after the first month of treatment and remained higher in tegoprubart-treated patients than in…
A recent phase 2 clinical trial, BESTOW, has indicated that tegoprubart, a novel anti-CD40L antibody therapy, is more effective than tacrolimus, the current standard of care, in preserving kidney function in first-time kidney transplant patients. The trial revealed that kidney graft function stabilized after the first month of treatment and remained higher in patients treated with tegoprubart compared to those treated with tacrolimus at each reported time point, with a statistically significant improvement in kidney function at 18 months.
Additionally, a recent analysis of the trial data found that tegoprubart also led to greater improvements in patient-reported health-related quality of life compared to tacrolimus. These findings will be presented at the ASN Kidney Week 2026, taking place from October 22–25.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
